Sharing is caring!


Excerpt

Lonza and ValenzaBio have entered an agreement for the accelerated manufacturing of VB421, an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) under evaluation for the treatment of thyroid eye disease (TED) and other autoimmune and fibrotic diseases. Lonza will leverage its global network and local operation capabilities, as well as its new manufacturing facility in Guangzhou (CN) for drug substance manufacturing to make treatment available for TED.


The two companies are collaborating to manufacture an innovative anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody called VB421, which is currently being assessed for the treatment of thyroid eye disease (TED) and other inflammatory disorders.

TED is an autoimmune disease that causes eye bulging and vision change, and may lead to blindness. VB421, which is in an IND-enabling program to support first-in-human studies, is engineered to bind IGF-1R, which is thought to be key in the pathogenesis of TED.

Lonza will provide drug substance (DS) and drug product manufacturing, the former of which will be carried out at its new state-of-the-art cGMP mammalian facility in Guangzhou (CN). Lonza’s industry-recognized and versatile GS Xceed® Expression System will also be utilised by the main production platform.
“The signing of the manufacturing agreement with ValenzaBio showcases our flexibility in supporting biotech companies of all sizes, and our focused commitment to enabling ValenzaBio to reach the full potential of their innovative therapies on accelerated timelines,” said Jennifer Cannon, Senior Vice President and Global Head of Mammalian Biologics at Lonza.

Tatyana Touzova, Chief Operating Officer of ValenzaBio, added, “Lonza has the knowledge, systems, and production capacity in place to proceed with optimal efficiency during these difficult times for global supply chains. Securing reliable biomanufacturing is a significant challenge for many smaller biopharmaceutical companies. We are grateful to be able to advance the VB421 program immediately in Lonza’s new state-of-the-art manufacturing facility.”

(Source: Lonza, 18th June 2021)


About Lonza
Lonza is a leading global partner to the pharmaceutical, biotech and nutrition markets. It delivers new and innovative medicines, combining technological insight with world-class manufacturing, scientific expertise and process excellence. For more information, visit www.lonza.com.

About ValenzaBio
Based in Bethesda, Md, ValenzaBio is a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory diseases. For more information, visit www.valenzabiotech.com.